Drugs / AD-117
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07495514 | Feb → Apr 2026 | hyperlipidemia, combined, 2 | Addpharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT07152873 | Dec 2025 → Feb 2026 overdue | hyperlipidemia, combined, 2 | Addpharma Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-01 | Addpharma Inc. | Regulatory 고지혈증 신규 조합 복합제 AD-117, 임상 1상 승인 addpharma.co.kr ↗
26일 식품의약품안전처에 따르면 애드파마는 'AD-117'에 대한 임상 1상을 승인 받았다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-01 | Addpharma Inc. | 고지혈증 신규 조합 복합제 AD-117, 임상 1상 승인 addpharma.co.kr ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07495514 ↗ |
| Route | Oral | “AD-117 1Tab., Per Oral” NCT07152873 ↗ |